SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PRCS
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Harold Engstrom who wrote (69)3/26/2003 3:33:27 PM
From: tuck   of 78
 
>>WALTHAM, Mass.--(BUSINESS WIRE)--March 26, 2003--PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS - News) today announced that the United States Food and Drug Administration (FDA) has accepted for review the Company's resubmission of its New Drug Application (NDA) for Plenaxis(TM). The FDA has confirmed that it is committed to complete its review of the NDA resubmission by August 27, 2003. The Company is seeking approval to market Plenaxis(TM) in the United States for use in a defined sub-population of advanced prostate cancer patients for whom the use of existing hormonal therapies may not be appropriate.<<

snip

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News